The week began with new partnerships formed in the life sciences industry as several firms entered into licensing deals and collaboration commitments. Here’s a look at the latest in life science licensing and collaboration deals. Telix Pharmaceuticals and Eli Lilly Telix Pharmaceuticals signed a license agreement with Eli Lilly and Company, granting Telix exclusive global rights to develop […]

Checkpoint inhibitors offer significant improvements in cancer care, yet even in combination with other checkpoint inhibitors or monoclonal antibodies, their results remain unsatisfactory for many. As Daniel Teper, CEO of Cytovia Therapeutics pointed out, “The best standard of care for advanced hepatocellular carcinoma (HCC) – a combination of atezolizumab (anti-PDL1 antibody) and bevacizumab (anti-VEGF antibody) – offers less […]

Cancer therapies are, increasingly, throwing one-two punches at cancer. For example, Sutro Biopharma presented Phase I data at the American Association for Cancer Research (AACR) Annual Meeting on April 8 showing that its lead compound, STRO-002, not only kills the tumor but also elicits immunogenic cell death. “STRO-002 is in phase I trials for ovarian and endometrial cancer. It’s a […]